Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DBI pseudogene 2 (DBIP2) is a processed pseudogene, meaning it is derived from the reverse transcription of mRNA from the parent DBI gene and lacks the ability to encode a functional protein. Pseudogenes like DBIP2 are typically non-functional as protein-coding genes due to mutations disrupting their coding potential or regulatory sequences, and there is no evidence that DBIP2 acts as a functional gene or therapeutic target. While some pseudogenes can play roles in gene regulation or disease, there is no published evidence for any specific biological or disease-related function for DBIP2. Key points explaining "is_incorrect": - DBIP2 is a pseudogene with no evidence of protein-coding ability. - It is not recognized as a canonical therapeutic target, such as a receptor, enzyme, transporter, or signaling molecule. - No functional, disease, or pharmacological information specific to DBIP2 is described in available references. Summary: DBI pseudogene 2 (DBIP2) is a processed pseudogene with no documented role in protein function, signaling, or therapeutic targeting. It is best classified as a genomic pseudogene locus with no established biomedical relevance.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DBI pseudogene 2 (DBIP2).